{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:29:50Z","timestamp":1783178990732,"version":"3.54.6"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004434","name":"University of Florence","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001671","name":"European Synchrotron Radiation Facility","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ejmech.2018.04.002","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T17:49:16Z","timestamp":1522777756000},"page":"363-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["2-Benzylpiperazine: A new scaffold for potent human carbonic anhydrase inhibitors. Synthesis, enzyme inhibition, enantioselectivity, computational and crystallographic studies and in\u00a0vivo activity for a new class of intraocular pressure lowering agents"],"prefix":"10.1016","volume":"151","author":[{"given":"Niccol\u00f2","family":"Chiaramonte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ferraroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Nocentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bartolucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaconcetta","family":"Durante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lucarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Chiapponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Dei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5881-6550","authenticated-orcid":false,"given":"Dina","family":"Manetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-3875","authenticated-orcid":false,"given":"Elisabetta","family":"Teodori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gratteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Masini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-0323","authenticated-orcid":false,"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5685-3403","authenticated-orcid":false,"given":"Maria Novella","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.04.002_bib1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.04.002_bib2","series-title":"Carbonic Anhydrases as Biocatalysts - from Theory to Medical and Industrial Applications","article-title":"Carbonic anhydrases: an overview","author":"Supuran","year":"2015"},{"key":"10.1016\/j.ejmech.2018.04.002_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3109\/14756366.2012.672983","article-title":"Structure-based drug discovery of carbonic anhydrase inhibitors","volume":"27","author":"Supuran","year":"2012","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib4","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1016\/j.bmcl.2010.05.009","article-title":"Carbonic anhydrase inhibitors","volume":"20","author":"Supuran","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.04.002_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/17460441.2015.1000857","article-title":"Discovery of novel inhibitors for the treatment of glaucoma","volume":"10","author":"Cholkar","year":"2015","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.04.002_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/1874764711205010083","article-title":"Recent patents on emerging therapeutics for the treatment of glaucoma, age related macular degeneration and uveitis","volume":"5","author":"Vadlapudi","year":"2012","journal-title":"Recent Pat. Biomed. Eng."},{"key":"10.1016\/j.ejmech.2018.04.002_bib7","series-title":"Carbonic Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial Applications","first-page":"157","article-title":"Membrane associated carbonic anhydrase IV (CA IV): a personal and historical perspective","author":"Waheed","year":"2014"},{"key":"10.1016\/j.ejmech.2018.04.002_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/bjophthalmol-2016-309376","article-title":"Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention","volume":"101","author":"Strong","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejmech.2018.04.002_bib9","series-title":"Carbonic Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial Applications","first-page":"271","article-title":"Carbonic Anhydrases and Brain PH in the Control of Neuronal Excitability","author":"Ruusuvuori","year":"2014"},{"key":"10.1016\/j.ejmech.2018.04.002_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/metabo8020025","article-title":"Carbonic anhydrase and metabolism","volume":"8","author":"Supuran","year":"2018","journal-title":"Metabolites"},{"key":"10.1016\/j.ejmech.2018.04.002_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/metabo7030048","article-title":"Carbonic anhydrase inhibition and the management of hypoxic tumors","volume":"7","author":"Supuran","year":"2017","journal-title":"Metabolites"},{"key":"10.1016\/j.ejmech.2018.04.002_bib12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/14737175.2016.1193009","article-title":"Carbonic anhydrase inhibition and the management of neuropathic pain","volume":"16","author":"Supuran","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejmech.2018.04.002_bib13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3109\/14756366.2015.1059333","article-title":"A\u00a0magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization","volume":"31","author":"Ozensoy Guler","year":"2016","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejmech.2015.07.026","article-title":"Piperazine scaffold: a remarkable tool in generation of diverse pharmacological agents","volume":"102","author":"Shaquiquzzaman","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib15","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1016\/j.bmcl.2015.07.060","article-title":"Synthesis of sulfonamides incorporating piperazinyl-ureido moieties and their carbonic anhydrase I, II, IX and XII inhibitory activity","volume":"25","author":"Congiu","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.04.002_bib16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ejmech.2013.09.027","article-title":"Carbonic anhydrase inhibitors. Synthesis of heterocyclic 4-substituted pyridine-3-sulfonamide derivatives and their inhibition of the human cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII","volume":"69","author":"S\u0142awi\u0144ski","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib17","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1016\/j.bmc.2015.07.024","article-title":"Synthesis and carbonic anhydrase I, II, IX and XII inhibitory activity of sulfamates incorporating piperazinyl-ureido moieties","volume":"23","author":"Congiu","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bioorg.2017.12.034","article-title":"Novel sulfonamide incorporating piperazine, aminoalcohol and 1,3,5-triazine structural motifs with carbonic anhydrase I, II and IX inhibitory action","volume":"77","author":"Havr\u00e1nkov\u00e1","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib19","unstructured":"J.M. Gerdes, D.B. Bolstad, M.R. Braden, A.W. Barany, 1-[(2'substituted)piperazin-1'-yl)Isoquinolines as Norepinephrine Transporter Inhibitor Therapeutics and Positron Emission Tomography Imaging Agents. WO2008115593."},{"key":"10.1016\/j.ejmech.2018.04.002_bib20","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.bmc.2005.11.013","article-title":"Diversity-oriented chemical modification of heparin: identification of charge-reduced N-acyl heparin derivatives having increased selectivity for heparin-binding proteins","volume":"14","author":"Huang","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib21","series-title":"2-aryl Indole Derivative as Antagonists of Tachykinins","author":"Chapman","year":"2003"},{"key":"10.1016\/j.ejmech.2018.04.002_bib22","unstructured":"D.E. Levy, M.S. Smyth, R.M. Scarbotough, Piperazine and Homopiperazine Compounds. US2003153556."},{"key":"10.1016\/j.ejmech.2018.04.002_bib23","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/ja00091a005","article-title":"Lack of Effect of the Length of Oligoglycine- and Oligo(ethylene glycol)-Derived para-Substituents on the Affinity of Benzenesulfonamides for Carbonic Anhydrase II in Solution","volume":"116","author":"Jain","year":"1994","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2018.04.002_bib24","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bmcl.2015.03.009","article-title":"Substituted piperazines as nootropic agents: 2- or 3-phenyl derivatives structurally related to the cognition-enhancer DM235","volume":"25","author":"Guandalini","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.04.002_bib25","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","article-title":"The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C","volume":"246","author":"Khalifah","year":"1971","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib26","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1136\/gutjnl-2014-308614","article-title":"Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP\u2013WT1\u2013TBL1 axis","volume":"65","author":"Zhang","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2018.04.002_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.60","article-title":"Role of carbonic anhydrases in skin wound healing","volume":"49","author":"Barker","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2018.04.002_bib28","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.04.002_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/14756366.2015.1122001","article-title":"How many carbonic anhydrase inhibition mechanisms exist?","volume":"31","author":"Supuran","year":"2016","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib30","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1073\/pnas.93.24.13589","article-title":"Crystal structure of the secretory form of membrane-associated human carbonic anhydrase IV at 2.8-\u00c5\u2009resolution","volume":"93","author":"Stams","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2018.04.002_bib31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1146\/annurev.anchem.1.031207.112945","article-title":"High-resolution mass spectrometers","volume":"1","author":"Marshall","year":"2008","journal-title":"Annu. Rev. Anal. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib32","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1021\/jm050333c","article-title":"Carbonic anhydrase Inhibitors:\u2009 stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II","volume":"48","author":"Menchise","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0223-5234(98)80059-7","article-title":"Carbonic anhydrase inhibitors \u2014 Part 52. Metal complexes of heterocyclic sulfonamides: a new class of strong topical intraocular pressure-lowering agents in rabbits","volume":"33","author":"Supuran","year":"1998","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib34","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1016\/j.bmcl.2005.04.056","article-title":"Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX","volume":"15","author":"Garaj","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.04.002_bib35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1747-0285.2011.01104.x","article-title":"In\u00a0vitro inhibition of human carbonic anhydrase I and II isozymes with natural phenolic compounds","volume":"77","author":"\u015eent\u00fcrk","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2018.04.002_bib36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/14756366.2011.597749","article-title":"A\u00a0new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology","volume":"27","author":"Fabrizi","year":"2012","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib37","series-title":"Evolving Methods for Macromolecular Crystallography: the Structural Path to the Understanding of the Mechanismof Action of CBRN Agents","first-page":"41","article-title":"Processing Diffraction Data with Mosflm","author":"Leslie","year":"2007"},{"key":"10.1016\/j.ejmech.2018.04.002_bib38","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1107\/S0907444996012255","article-title":"Refinement of macromolecular structures by the maximum-likelihood method","volume":"53","author":"Murshudov","year":"1997","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2018.04.002_bib39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1107\/S090744491200251X","article-title":"JLigand: a graphical tool for the CCP4 template-restraint library","volume":"68","author":"Lebedev","year":"2012","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2018.04.002_bib40","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2018.04.002_bib41","series-title":"Int. Tables\u00a0for Crystallography. Vol. F: Crystallography of Biological Macromolecules","first-page":"720","article-title":"The ARP\/wARP suite for automated construction and refinement of protein models","author":"Lamzin","year":"2001"},{"key":"10.1016\/j.ejmech.2018.04.002_bib42","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/prot.10286","article-title":"Structure validation by C\u03b1 geometry: \u03d5,\u03c8 and C\u03b2 deviation","volume":"50","author":"Lovell","year":"2003","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2018.04.002_bib43","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_bib44","doi-asserted-by":"crossref","first-page":"10692","DOI":"10.1021\/acs.jmedchem.6b01389","article-title":"Benzenesulfonamides incorporating flexible triazole moieties are highly effective carbonic anhydrase inhibitors: synthesis and kinetic, crystallographic, computational, and intraocular pressure lowering investigations","volume":"59","author":"Nocentini","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.002_sref45","series-title":"Schr\u00f6dinger, Schr\u00f6dinger Suite Release 2016-1, Schr\u00f6dinger","year":"2016"},{"key":"10.1016\/j.ejmech.2018.04.002_bib45a","unstructured":"Maestro v.10.5."},{"key":"10.1016\/j.ejmech.2018.04.002_bib45b","unstructured":"Epik, v.3.5."},{"key":"10.1016\/j.ejmech.2018.04.002_bib45c","unstructured":"Macromodel v.11.1."},{"key":"10.1016\/j.ejmech.2018.04.002_bib45d","unstructured":"Glide, v.7.0."},{"key":"10.1016\/j.ejmech.2018.04.002_bib45e","unstructured":"Prime, v.4.3."},{"key":"10.1016\/j.ejmech.2018.04.002_bib46","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/prot.23106","article-title":"The VSGB2.0 model: a next generation energy model for high resolution protein structure modeling","volume":"79","author":"Li","year":"2011","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2018.04.002_bib47","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0039-6257(01)00211-9","article-title":"The Draize eye test","volume":"45","author":"Wilhelmus","year":"2001","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ejmech.2018.04.002_bib48","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/bjo.2006.099838","article-title":"A\u00a0topical nitric oxide-releasing dexamethasone derivative: effects on intraocular pressure and ocular haemodynamics in a rabbit glaucoma model","volume":"90","author":"Galassi","year":"2006","journal-title":"Br. J. Ophthalmol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418303295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418303295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T22:53:36Z","timestamp":1660776816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418303295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":53,"alternative-id":["S0223523418303295"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.04.002","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2-Benzylpiperazine: A new scaffold for potent human carbonic anhydrase inhibitors. Synthesis, enzyme inhibition, enantioselectivity, computational and crystallographic studies and in\u00a0vivo activity for a new class of intraocular pressure lowering agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}